ExploreWatchlistsPricing
  1. JP-listed companies
  2. Human Metabolome Technologies, Inc.
  3. Financials
  4. Revenue growth (%)

Human Metabolome Technologies, Inc. (6090)

Market cap
¥3.7B
P/E ratio
17.3x
Provides high-sensitivity analysis of metabolic compounds to pharmaceutical companies, research institutions, and manufacturers to support drug development and product testing.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue growth (%) YoY (%)
Jun 30, 20258.1+127.45%
Jun 30, 20243.6-42.51%
Jun 30, 20236.2-29.67%
Jun 30, 20228.8+1666.00%
Jun 30, 20210.5-98.53%
Jun 30, 202034.1+524.36%
Jun 30, 20195.5-149.23%
Mar 31, 2019-11.1-521.67%
Mar 31, 20182.6-84.66%
Mar 31, 201717.2+25.55%
Mar 31, 201613.7+9.37%
Mar 31, 201512.5-45.65%
Mar 31, 201423-567.07%
Mar 31, 2013-4.9

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat